All patients received anti-HER2 TKI therapy (including pyrotinib and lapatinib) in 28-day cycles. No unexpected toxic effects were reported. After progression following TKI therapy, T-DXd exhibited notable antitumor activity, although no significant efficacy differences were observed among ADC, mAb, and TKI groups.

The patient received first-line docetaxel, trastuzumab, and pyrotinib (PyroHT) and achieved a partial response; however, progression was observed after ten cycles. Following multidisciplinary review, her treatment was changed to trastuzumab deruxtecan (T-DXd), resulting in significant symptom relief and radiologic regression of the breast lesions...Sequential HER2-targeted therapy provided meaningful clinical benefit, though resistance ultimately developed. We present the case of a 53-year-old woman with HER2-positive advanced PLC presenting with an IBC phenotype, providing insight into the diagnostic process and treatment course in this rare clinical scenario.

P2, N=76, Recruiting, Fifth Affiliated Hospital, Sun Yat-Sen University; Fifth Affiliated Hospital, Sun Yat-Sen University

P4, N=568, Recruiting, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital | Not yet recruiting --> Recruiting

P1/2, N=83, Recruiting, Virginia Commonwealth University | Trial completion date: May 2027 --> Jan 2031 | Trial primary completion date: May 2026 --> Dec 2029

P1/2, N=324, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Nov 2023 --> Dec 2026

FGFR2 is lowly expressed in DFU and can exert a protective effect by activating the PI3K/Akt pathway. It is a candidate diagnostic biomarker and potential therapeutic target for DFU.

For patients with HER2-positive advanced breast cancer, diarrhea that occurs during pyrotinib-based therapy maybe a prognostic marker of longer OS.

P3, N=280, Not yet recruiting, Fudan University

The LAR subtype harbors two therapeutic vulnerabilities: ERBB2 mutation-driven kinase activation; and senescence-mediated immune evasion. The LAR-S signature enables precise patient stratification and supports senescence-targeted and immunotherapy combination strategies as promising approaches for this refractory TNBC subtype.

N+T in patients with HER2-mutant metastatic TNBC appeared to prolong responses versus neratinib alone, representing a novel approach for biomarker-defined metastatic TNBC patients. Based on these and previously published data, neratinib-based combinations are endorsed by NCCN guidelines for patients with hormone receptor-positive or -negative metastatic breast cancer with activating HER2 mutations.